KYNB
Kyntra Bio Inc.

4,717
Mkt Cap
$28.37M
Volume
10,107.00
52W High
$12.60
52W Low
$4.85
PE Ratio
0.22
KYNB Fundamentals
Price
$7.14
Prev Close
$7.01
Open
$7.00
50D MA
$7.14
Beta
1.91
Avg. Volume
35,202.17
EPS (Annual)
$45.36
P/B
-0.96
Rev/Employee
$189,411.77
$0.5925
Loading...
Loading...
News
all
press releases
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·1mo ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -5.50% and +17.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
<
...
1
>

Latest KYNB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.